volume 1866 issue 6 pages 165741

Atorvastatin attenuates obese-induced kidney injury and impaired renal organic anion transporter 3 function through inhibition of oxidative stress and inflammation

Nattavadee Pengrattanachot 1
Rada Cherngwelling 1
Krit Jaikumkao 2
Anchalee Pongchaidecha 1
Laongdao Thongnak 1
Myat Theingi Swe 3, 4
Varanuj Chatsudthipong 5
Anusorn Lungkaphin 6
Publication typeJournal Article
Publication date2020-06-01
scimago Q1
wos Q1
SJR1.432
CiteScore6.8
Impact factor4.2
ISSN09254439, 1879260X
Molecular Biology
Molecular Medicine
Abstract
An excessive consumption of high-fat diet can lead to the alterations of glucose and lipid metabolism, impaired insulin signaling and increased ectopic lipid accumulation resulting in renal lipotoxicity and subsequent renal dysfunction. Atorvastatin is a lipid-lowering drug in clinical treatment. Several studies have reported that atorvastatin has several significant pleiotropic effects including anti-inflammatory, antioxidant, and anti-apoptotic effects. However, the effects of atorvastatin on metabolic disturbance and renal lipotoxicity in obesity are not fully understood. In this study, obesity in rat was developed by high-fat diet (HFD) feeding for 16 weeks. After that, the HFD-fed rats were received either a vehicle (HF), atorvastatin (HFA) or vildagliptin (HFVIL), by oral gavage for 4 weeks. We found that HF rats showed insulin resistance, visceral fat expansion and renal lipid accumulation. Impaired renal function and renal organic anion transporter 3 (Oat3) function and expression were also observed in HF rats. The marked increases in MDA level, renal injury and NF-κB, TGF-β, NOX-4, PKC-α expression were demonstrated in HF rats. Atorvastatin or vildagliptin treatment attenuated insulin resistance and renal lipid accumulation-induced lipotoxicity in HFA and HFVIL rats. Moreover, the proteins involved in renal inflammation, fibrosis, oxidative stress and apoptosis were attenuated leading to improved renal Oat3 function and renal function in the treated groups. Interestingly, atorvastatin showed higher efficacy than vildagliptin in improving insulin resistance, renal lipid accumulation and in exerting renoprotective effects in obesity-induced renal injury and impaired renal Oat3 function. • Atorvastatin is able to ameliorate insulin resistance in high-fat induced obese rats. • Atorvastatin can attenuate renal lipid accumulation in high-fat induced obese rats. • Atorvastatin can reduce oxidative stress and proinflammatory cytokines in the kidney of high-fat induced obese rats. • Impaired renal Oat3 function and renal function are restored by atorvastatin treatment.
Found 
Found 

Top-30

Journals

1
2
Antioxidants
2 publications, 4.88%
Frontiers in Pharmacology
2 publications, 4.88%
Toxicology and Applied Pharmacology
2 publications, 4.88%
Diabetes, Obesity and Metabolism
2 publications, 4.88%
Chemico-Biological Interactions
2 publications, 4.88%
Aging
1 publication, 2.44%
ACS Applied Bio Materials
1 publication, 2.44%
BMC Nephrology
1 publication, 2.44%
Molecules
1 publication, 2.44%
Frontiers in Molecular Biosciences
1 publication, 2.44%
Frontiers in Microbiology
1 publication, 2.44%
Archives of Pharmacal Research
1 publication, 2.44%
Carbohydrate Polymers
1 publication, 2.44%
Life Sciences
1 publication, 2.44%
Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids
1 publication, 2.44%
Pharmacology and Therapeutics
1 publication, 2.44%
Journal of Cellular Physiology
1 publication, 2.44%
Journal of Biochemical and Molecular Toxicology
1 publication, 2.44%
Small Structures
1 publication, 2.44%
Archives of Physiology and Biochemistry
1 publication, 2.44%
Anais da Academia Brasileira de Ciencias
1 publication, 2.44%
EMBO Reports
1 publication, 2.44%
Advances in Pharmacological and Pharmaceutical Sciences
1 publication, 2.44%
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
1 publication, 2.44%
Integrative Medicine in Nephrology and Andrology
1 publication, 2.44%
Molecular Nutrition and Food Research
1 publication, 2.44%
Medicina
1 publication, 2.44%
Pharmaceutics
1 publication, 2.44%
Journal of Clinical Biochemistry and Nutrition
1 publication, 2.44%
BMC Complementary Medicine and Therapies
1 publication, 2.44%
1
2

Publishers

1
2
3
4
5
6
7
8
9
Elsevier
9 publications, 21.95%
MDPI
7 publications, 17.07%
Wiley
6 publications, 14.63%
Springer Nature
4 publications, 9.76%
Frontiers Media S.A.
4 publications, 9.76%
Taylor & Francis
2 publications, 4.88%
Impact Journals
1 publication, 2.44%
American Chemical Society (ACS)
1 publication, 2.44%
Pharmaceutical Society of Korea
1 publication, 2.44%
SciELO
1 publication, 2.44%
European Molecular Biology Organization
1 publication, 2.44%
Hindawi Limited
1 publication, 2.44%
Ovid Technologies (Wolters Kluwer Health)
1 publication, 2.44%
The Society for Free Radical Research Japan
1 publication, 2.44%
Oriental Scientific Publishing Company
1 publication, 2.44%
1
2
3
4
5
6
7
8
9
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
41
Share
Cite this
GOST |
Cite this
GOST Copy
Pengrattanachot N. et al. Atorvastatin attenuates obese-induced kidney injury and impaired renal organic anion transporter 3 function through inhibition of oxidative stress and inflammation // Biochimica et Biophysica Acta - Molecular Basis of Disease. 2020. Vol. 1866. No. 6. p. 165741.
GOST all authors (up to 50) Copy
Pengrattanachot N., Cherngwelling R., Jaikumkao K., Pongchaidecha A., Thongnak L., Swe M., Chatsudthipong V., Lungkaphin A. Atorvastatin attenuates obese-induced kidney injury and impaired renal organic anion transporter 3 function through inhibition of oxidative stress and inflammation // Biochimica et Biophysica Acta - Molecular Basis of Disease. 2020. Vol. 1866. No. 6. p. 165741.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.bbadis.2020.165741
UR - https://doi.org/10.1016/j.bbadis.2020.165741
TI - Atorvastatin attenuates obese-induced kidney injury and impaired renal organic anion transporter 3 function through inhibition of oxidative stress and inflammation
T2 - Biochimica et Biophysica Acta - Molecular Basis of Disease
AU - Pengrattanachot, Nattavadee
AU - Cherngwelling, Rada
AU - Jaikumkao, Krit
AU - Pongchaidecha, Anchalee
AU - Thongnak, Laongdao
AU - Swe, Myat Theingi
AU - Chatsudthipong, Varanuj
AU - Lungkaphin, Anusorn
PY - 2020
DA - 2020/06/01
PB - Elsevier
SP - 165741
IS - 6
VL - 1866
PMID - 32101757
SN - 0925-4439
SN - 1879-260X
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2020_Pengrattanachot,
author = {Nattavadee Pengrattanachot and Rada Cherngwelling and Krit Jaikumkao and Anchalee Pongchaidecha and Laongdao Thongnak and Myat Theingi Swe and Varanuj Chatsudthipong and Anusorn Lungkaphin},
title = {Atorvastatin attenuates obese-induced kidney injury and impaired renal organic anion transporter 3 function through inhibition of oxidative stress and inflammation},
journal = {Biochimica et Biophysica Acta - Molecular Basis of Disease},
year = {2020},
volume = {1866},
publisher = {Elsevier},
month = {jun},
url = {https://doi.org/10.1016/j.bbadis.2020.165741},
number = {6},
pages = {165741},
doi = {10.1016/j.bbadis.2020.165741}
}
MLA
Cite this
MLA Copy
Pengrattanachot, Nattavadee, et al. “Atorvastatin attenuates obese-induced kidney injury and impaired renal organic anion transporter 3 function through inhibition of oxidative stress and inflammation.” Biochimica et Biophysica Acta - Molecular Basis of Disease, vol. 1866, no. 6, Jun. 2020, p. 165741. https://doi.org/10.1016/j.bbadis.2020.165741.